August 2009 Volume 27 Number 8, pp 675 - 776
Visit Nature Biotechnology online to browse the journal.
Now available at http://links.ealert.nature.com/ctt?kn=47&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access to Nature Biotechnology online. To purchase a subscription, please visit:
http://links.ealert.nature.com/ctt?kn=1&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=131&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
Bioentrepreneur: an online resource for budding business in the life sciences.
http://links.ealert.nature.com/ctt?kn=4&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
STOP CLONING!
Buy pre-cloned promoters and 3'UTRs delivered in luciferase reporter vectors. Measure miRNA function, promoter induction, or the effects of transcription factor binding quickly and easily. Visit SwitchGear Genomics and explore our online catalog of genome-wide, assay-ready promoter and UTR reporters.
http://links.ealert.nature.com/ctt?kn=151&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
=====================================================================
=========================== ADVERTISEMENT ===========================
PepChip kinome profiling introduction offer
http://links.ealert.nature.com/ctt?kn=119&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
Have you ever wanted to see a panoramic view of kinase activities in
cells and tissues? Now you can with kinome profiling. The value of
PepChip Kinomics has been shown independently in over 22 high-level papers.
This is your chance to see what kinome profiling can do for you.
Check out our special offer now.
http://links.ealert.nature.com/ctt?kn=133&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
=====================================================================
=========================== ADVERTISEMENT ===========================
FREE ARTICLE
Infectious disease: Rapamycin's immunostimulatory potential
Despite Rapamune's current use as an immunosuppressant, Emory University researchers think it has promise as an immunostimulatory vaccine adjuvant. Find out more by reading the first in-depth analysis of the scientific and commercial potential of the work in SciBX: Science-Business eXchange.
Full text: http://links.ealert.nature.com/ctt?kn=41&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
PDF: http://links.ealert.nature.com/ctt?kn=86&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
ACCESS 30 FREE ARTICLES from the SciBX Cover Story Archive HERE:
http://links.ealert.nature.com/ctt?kn=154&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
=====================================================================
=========================== ADVERTISEMENT ===========================
BIOPARTNERING
Visit our Biopartnering site to view Company Profiles and Partnership Opportunities:
http://links.ealert.nature.com/ctt?kn=8&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
=====================================================================
=========================== ADVERTISEMENT ===========================
FREE ARTICLE
Huntington's Disease: A major advance
Johns Hopkins researchers may have solved a central mystery of Huntington's disease: why the mutant form of the huntingtin protein occurs throughout the body and yet causes
pathology primarily in the brain. The proposed target, Rhes, also looks to be druggable.
Find out more by reading the first in-depth analysis of the scientific and commercial
potential of the work in SciBX: Science-Business eXchange.
Full text: http://links.ealert.nature.com/ctt?kn=34&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
PDF: http://links.ealert.nature.com/ctt?kn=179&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
ACCESS 20 FREE ARTICLES from the SciBX Cover Story Archive HERE
http://links.ealert.nature.com/ctt?kn=182&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
=====================================================================
=========================== ADVERTISEMENT ===========================
The University of Miami, Scripps Florida and Nature Publishing Group present
MIAMI 2010 WINTER SYMPOSIUM
Targeting Cancer Invasion and Metastasis
February 21-24, 2010
Miami Beach, FL, USA
This meeting will focus on recent advances in our knowledge of basic molecular pathways of invasion, migration and immune surveillance and how that knowledge can be translated into new clinical concepts for diagnosis and therapy.
Register Today: http://links.ealert.nature.com/ctt?kn=199&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
=====================================================================
----------------------
EDITORIAL
----------------------
A blueprint for biotech's blues p675
The strategy outlined in the UK's Life Sciences Blueprint is unlikely to address the British biotech sector's woes or help it regain prominence and success.
doi:10.1038/nbt0809-675
http://links.ealert.nature.com/ctt?kn=106&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
----------------------
NEWS
----------------------
Brand biologics grab 12 years' exclusivity, for now pp677 - 678
Randy Osborne
doi:10.1038/nbt0809-677
http://links.ealert.nature.com/ctt?kn=110&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
Awards bridge 'valley of death' p678
Emma Dorey
doi:10.1038/nbt0809-678
http://links.ealert.nature.com/ctt?kn=113&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
J&J's billion dollar punt on anti-amyloid antibody pp679 - 681
Cormac Sheridan
doi:10.1038/nbt0809-679
http://links.ealert.nature.com/ctt?kn=56&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
Virus stalls Genzyme plant p681
Victor Bethencourt
doi:10.1038/nbt0809-681a
http://links.ealert.nature.com/ctt?kn=72&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
Stem cell funding widens p681
James Netterwald
doi:10.1038/nbt0809-681b
http://links.ealert.nature.com/ctt?kn=85&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
Bye-bye WilBio p682
Nazlie Latefi
doi:10.1038/nbt0809-682a
http://links.ealert.nature.com/ctt?kn=52&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
GM fish ice cream p682
Anna Meldolesi
doi:10.1038/nbt0809-682b
http://links.ealert.nature.com/ctt?kn=45&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
Novo awaits green light for diabetes drug pp682 - 685
Mike May
doi:10.1038/nbt0809-682c
http://links.ealert.nature.com/ctt?kn=25&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
Cellulosic at the pump p684
Brady Huggett
doi:10.1038/nbt0809-684a
http://links.ealert.nature.com/ctt?kn=37&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
Plasma firms denied merger p684
Brady Huggett
doi:10.1038/nbt0809-684b
http://links.ealert.nature.com/ctt?kn=35&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
Genzyme's Lumizyme clears bioequivalence hurdles p685
Mark Ratner
doi:10.1038/nbt0809-685a
http://links.ealert.nature.com/ctt?kn=21&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
Peru embraces biotech p685
Veronica Guerrero
doi:10.1038/nbt0809-685b
http://links.ealert.nature.com/ctt?kn=44&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
Illumina's cut-price genome scan p685
Malorye Allison
doi:10.1038/nbt0809-685c
http://links.ealert.nature.com/ctt?kn=48&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
DATA PAGE
Signs of life in Q2 p686
Walter Yang
doi:10.1038/nbt0809-686
http://links.ealert.nature.com/ctt?kn=166&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
NEWS FEATURES
Immunology's quiet upheaval pp687 - 689
Several drug programs aim to restore the balance between regulatory T cells and T helper 17 (Th17) cells in autoimmune disease. But as therapies advance in the clinic, new discoveries are challenging the fundamental principle that T-cell lineages, once established, don't change. Ken Garber reports.
Ken Garber
doi:10.1038/nbt0809-687
http://links.ealert.nature.com/ctt?kn=168&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
The cold rush pp690 - 692
More than 40 companies are now engaged in bioprospecting in the Arctic. Hannah Hoag gauges the biotech potential buried beneath the ice and snow.
Hannah Hoag
doi:10.1038/nbt0809-690
http://links.ealert.nature.com/ctt?kn=152&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
----------------------
BIOENTREPRENEUR
----------------------
BUILDING A BUSINESS
Building today's platform company
For entrepreneurs developing innovative technology, the platform business model is making a comeback.
Guido Lanza
doi:10.1038/bioe.2009.6
http://links.ealert.nature.com/ctt?kn=39&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
----------------------
OPINION AND COMMENT
----------------------
CORRESPONDENCE
And then there were two: use of hESC lines pp696 - 697
Christopher Thomas Scott, Jennifer B McCormick and Jason Owen-Smith
doi:10.1038/nbt0809-696
http://links.ealert.nature.com/ctt?kn=156&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
BARDA's budget pp698 - 699
Lynn C Klotz and Alan Pearson
doi:10.1038/nbt0809-698
http://links.ealert.nature.com/ctt?kn=66&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
Reply to BARDA's budget p699
doi:10.1038/nbt0809-699
http://links.ealert.nature.com/ctt?kn=90&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
Detection of genetically modified organisms - closing the gaps pp700 - 701
Dany Morisset et al.
doi:10.1038/nbt0809-700
http://links.ealert.nature.com/ctt?kn=109&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
The contraction of agbiotech product quality innovation pp702 - 704
Gregory D Graff, David Zilberman and Alan B Bennett
doi:10.1038/nbt0809-702
http://links.ealert.nature.com/ctt?kn=118&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
COMMENTARY
Beyond the biotech IPO: a brave new world pp705 - 709
After a decade of significant challenges, biotech's long-term sustainability depends on making fundamental changes to its traditional business model.
Bruce L Booth
doi:10.1038/nbt0809-705
http://links.ealert.nature.com/ctt?kn=143&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
----------------------
FEATURES
----------------------
Public biotech 2008 - the numbers pp710 - 721
The sour global economy has left many small public firms gasping for air.
Brady Huggett, John Hodgson and Riku Lahteenmaki
doi:10.1038/nbt0809-710
http://links.ealert.nature.com/ctt?kn=122&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
PATENTS
Stem cell patents: a landscape analysis pp722 - 726
An evaluation of the development of innovation in stem cell technologies by network analysis of stem cell patent filings.
Antoinette F Konski and Doris J F Spielthenner
doi:10.1038/nbt0809-722
http://links.ealert.nature.com/ctt?kn=71&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
Recent patent applications in biomarkers p727
doi:10.1038/nbt0809-727
http://links.ealert.nature.com/ctt?kn=132&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Synthetic metabolic pipelines pp728 - 729
Controlling the spatial organization of sequential metabolic enzymes may provide a general strategy for increasing the production of valuable compounds.
Matthew P DeLisa and Robert J Conrado
doi:10.1038/nbt0809-728
http://links.ealert.nature.com/ctt?kn=58&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
Metabolic engineering without plasmids pp729 - 731
Tandem gene duplication is harnessed to genetically engineer Escherichia coli, enabling sustained expression of metabolic products.
Aashiq H Kachroo, Makkuni Jayaram and Paul A Rowley
doi:10.1038/nbt0809-729
http://links.ealert.nature.com/ctt?kn=29&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
Universal cell-free protein synthesis pp731 - 732
Unstructured translation-initiation sequences enable protein synthesis in cell extracts from multiple organisms.
James R Swartz
doi:10.1038/nbt0809-731
http://links.ealert.nature.com/ctt?kn=31&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
Next-generation quantum dots pp732 - 733
Quantum dots that are small and non-blinking offer new opportunities for dynamic single-molecule imaging in live cells.
Andrew M Smith and Shuming Nie
doi:10.1038/nbt0809-732
http://links.ealert.nature.com/ctt?kn=54&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
----------------------
RESEARCH HIGHLIGHTS
----------------------
Research highlights p734
Laura De Francesco, Markus Elsner, Peter Hare and Craig Mak
doi:10.1038/nbt0809-734
http://links.ealert.nature.com/ctt?kn=121&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
----------------------
COMPUTATIONAL BIOLOGY
----------------------
PERSPECTIVE
The Systems Biology Graphical Notation pp735 - 741
A group of scientists in the systems biology community propose visual conventions for drawing biological diagrams.
Nicolas Le Novère et al.
doi:10.1038/nbt.1558
Abstract: http://links.ealert.nature.com/ctt?kn=26&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=36&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
----------------------
RESEARCH
----------------------
BRIEF COMMUNICATIONS
Variation in the safety of induced pluripotent stem cell lines pp743 - 745
The safety of induced pluripotent stem cells seems to depend on how they were generated. Miura et al. examine the effects of the c-myc transgene, tissue of origin and selection method on the tumor-forming propensity of iPS-cell derivatives.
Kyoko Miura et al.
doi:10.1038/nbt.1554
Abstract: http://links.ealert.nature.com/ctt?kn=7&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=27&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
ARTICLES
Species-independent translational leaders facilitate cell-free expression pp747 - 752
Initiation of translation is an obstacle in the development of eukaryotic systems for cell-free protein synthesis. Mureev et al. describe a translational leader sequence that efficiently drives protein production in cell lysates from several eukaryotes and prokaryotes and use this sequence to develop a cell-free system based on Leishmania tarentolae.
Sergei Mureev, Oleksiy Kovtun, Uyen T T Nguyen and Kirill Alexandrov
doi:10.1038/nbt.1556
Abstract: http://links.ealert.nature.com/ctt?kn=5&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=197&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
Synthetic protein scaffolds provide modular control over metabolic flux pp753 - 759
Engineered metabolic pathways are usually devoid of the regulatory mechanisms characteristic of natural metabolism. Using pathways not normally found in E. coli, Dueber et al. show that synthetic scaffolds built using protein-protein interaction domains can boost yields of mevalonate and glucaric acid.
John E Dueber et al.
doi:10.1038/nbt.1557
Abstract: http://links.ealert.nature.com/ctt?kn=12&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=150&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
Stabilized gene duplication enables long-term selection-free heterologous pathway expression pp760 - 765
Although new metabolic pathways are generally introduced into bacteria on plasmids, this approach is limited by declining productivity after several generations. Tyo et al. describe a method for chromosome engineering that enables sustained production of a biopolymer or a nutraceutical.
Keith E J Tyo, Parayil Kumaran Ajikumar and Gregory Stephanopoulos
doi:10.1038/nbt.1555
Abstract: http://links.ealert.nature.com/ctt?kn=155&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=183&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
LETTER
Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo pp767 - 771
Although never demonstrated in humans, exchange of the antigen-binding regions of IgG4 antibodies with different specificities could complicate certain antibody therapies. Labrijn et al. show that Fab-arm exchange occurs in patients and propose that a single mutation can inhibit the process.
Aran F Labrijn et al.
doi:10.1038/nbt.1553
Abstract: http://links.ealert.nature.com/ctt?kn=59&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=107&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
----------------------
CAREERS AND RECRUITMENT
----------------------
Seeding a skilled workforce pp773 - 775
How might the Indian government spur the development of a biotech workforce with a broader set of skills?
Gayatri Saberwal
doi:10.1038/nbt0809-773
http://links.ealert.nature.com/ctt?kn=116&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
PEOPLE
People p776
doi:10.1038/nbt0809-776
http://links.ealert.nature.com/ctt?kn=140&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Nature Lab Offers is coming September 24!
Save money on products used in your lab: cell cultures, antibodies, lab consumables, imaging equipment, DNA and RNA isolation products, gene targeting equipment, centrifuges, and so much more.
Register today and be the first to receive your Nature Lab Offers coupons.
http://links.ealert.nature.com/ctt?kn=40&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
=====================================================================
You have been sent this Table of Contents Alert because you have opted in to
receive it. You can change or discontinue your e-mail alerts at any time,
by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=173&m=33824906&r=MzA1MjI5MDUzNQS2&b=2&j=NTUyNjAyNTkS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================
